1,3-二甲氧基-2-(甲基硫代)苯 | 33617-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1,3-二甲氧基-2-(甲基硫代)苯
• 中文别名: 1,3-二甲氧基-2-甲基硫代苯
• 英文名称: (2,6-dimethoxyphenyl)(methyl)sulfane
• 英文别名: 1,3-Dimethoxy-2-(methylthio)benzene；1,3-dimethoxy-2-methylsulfanylbenzene
• CAS: 33617-67-3
• 化学式: C₉H₁₂O₂S
• mdl: MFCD00010334
• 分子量: 184.259
• InChiKey: UASQOZQFGVJMFY-UHFFFAOYSA-N

物化性质

• 熔点：
  79 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  43.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2930909090
• 储存条件：
  存储条件：2-8℃，请置于干燥处并密封保存。

反应信息

• 作为反应物：
  描述：

  1,3-二甲氧基-2-(甲基硫代)苯 在 乙酸铵 、 lithium aluminium tetrahydride 、 硫酸 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 3.58h， 生成 2-(2,4-Dimethoxy-3-methylsulfanyl-phenyl)-ethylamine
  参考文献：
  名称：

  拟精神病药物的硫类似物。甲斯卡林和异麦斯卡林的单硫代类似物。

  摘要：

  合成并表征了两种麦斯卡林的单硫代类似物和2,3,4-三甲氧基苯乙胺（异麦斯卡汀）的三种单硫代类似物。发现只有两种甲斯卡灵类似物（3-和4-硫代甲斯卡林）是拟精神病药，其功效分别是甲斯卡林的6倍和12倍。所有这五种化合物均可在体外用作牛血浆单胺氧化酶的底物，但酶促降解程度与拟精神药物效价之间没有明显的正相关关系。

  DOI：

  10.1021/jm00143a017
• 作为产物：
  描述：

  2,6-二甲氧基苯胺 在 sodium ethanolate 作用下， 生成 1,3-二甲氧基-2-(甲基硫代)苯
  参考文献：
  名称：

  Baliah,V.; Rangarajan,T., Journal of the Indian Chemical Society, 1961, vol. 38, # 1, p. 33 - 40

  摘要：

  DOI：

文献信息

• Reaction of Arynes with Sulfoxides
  作者：Hong-Ying Li、Li-Juan Xing、Mei-Mei Lou、Han Wang、Rui-Hua Liu、Bin Wang

  DOI：10.1021/ol5036326

  日期：2015.3.6

  A S–O bond insertion reaction of sulfoxides with arynes is reported. This reaction represents a rare instance of semipolar single bond insertion in aryne chemistry. The study of mechanism indicates that a sulfur ylide triggered by aryne is the key intermediate, which further transfers its methylene group to carbonyl compounds to give epoxides and thioethers through a sequential process.

  据报道亚砜与芳烃的AS-O键插入反应。该反应代表了芳烃化学中半极性单键插入的罕见情况。机理研究表明，芳烃引发的硫叶立德是关键中间体，它通过一个连续的过程进一步将其亚甲基转移至羰基化合物，从而生成环氧化物和硫醚。
• Method for orthometalation of a carbocyclic aromatic derivative bearing at least an electron donor group
  申请人：Rhodia Chimie

  公开号：US06384273B1

  公开（公告）日：2002-05-07

  The invention concerns a method for orthometalation of a carbocyclic aromatic derivative bearing at least an electron donor group, characterised in that it consists in reacting said carbocyclic aromatic derivative with an efficient amount of at least one alkaline metal in the presence of a compound of formula (I): RX, wherein: R represents a hydrocarbon radical having 1 to 20 carbon atoms which can be a saturated or unsaturated, linear or branched, acyclic aliphatic radical; a saturated or unsaturated, monocyclic or polycyclic cycloaliphatic radical; a saturated or unsaturated, linear or branched aliphatic radical bearing a cyclic substituent; and X represents a bromine or chlorine atom.

  该发明涉及一种用于对至少带有一个电子供体基团的碳环芳衍生物进行正金属化的方法，其特征在于将所述碳环芳衍生物与至少一种碱金属的有效量在式(I)的化合物的存在下反应，其中：R代表具有1至20个碳原子的烃基，可以是饱和或不饱和的，线性或支链的，无环的脂肪基；饱和或不饱和的，单环或多环的环脂肪基；具有一个环替代基的饱和或不饱和的，线性或支链的脂肪基；X代表溴或氯原子。
• Organic compounds
  申请人：Novartis AG

  公开号：US08084448B2

  公开（公告）日：2011-12-27

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式为的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖耐受性、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗，以及伴随2型糖尿病的情况，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常和其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• CHROMENE COMPOUND AND CURABLE COMPOSITION
  申请人：TOKUYAMA CORPORATION

  公开号：US20140225050A1

  公开（公告）日：2014-08-14

  A chromene compound which has a sulfur-containing substituent represented by the following formula (2) at the 6-position and/or 7-position carbon atom of an indeno (2,1-f)naphtho(1,2-b)pyran structure and is excellent in photochromic properties and stability at a high temperature. (In the above formula, ring X is an aromatic hydrocarbon ring or aromatic heterocyclic ring, R 3 and R 4 are each independently an alkyl group, haloalkyl group, cycloalkyl group, alkoxy group, amino group, heterocyclic group containing a ring member nitrogen atom and bonded to the ring X bonded thereto via the nitrogen atom, halogen atom, aryloxy group or aryl group, and “a” is an integer of 0 to 4.)

  一种含有硫取代基的色烯化合物，其在indeno（2,1-f）naphtho（1,2-b）pyran结构的6-位和/或7-位碳原子处，用以下式子（2）表示，并且具有优异的光致变色性能和高温稳定性。（在上述式子中，环X是芳香族烃环或芳香族杂环环，R3和R4各自独立地是烷基，卤代烷基，环烷基，烷氧基，氨基，含有环成员氮原子并通过氮原子与环X结合的杂环基，卤素原子，芳氧基或芳基，而“a”是0到4的整数。）
• ORGANIC COMPOUNDS
  申请人：Neubert Alan

  公开号：US20090181928A1

  公开（公告）日：2009-07-16

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压以及大、小血管缺血性疾病有关的胰岛素抵抗。这些疾病包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症，以及其他显示胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。

表征谱图